Role of Short-Term Radiotherapy in Cancer of Large Bowel
Phase 2
- Conditions
- Rectal Adenocarcinoma.Malignant neoplasm of rectum
- Registration Number
- IRCT2016121424266N2
- Lead Sponsor
- Deputy of Research, Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Inclusion Criteria:
Rectal Adenocarcinoma Confirmed by Pathology; Both Genders; Ages 18 to 80; Clinical Stages T3-4 or Lymph node Positive by MRI or Endosonography; Tumor Location 5 to 15 cm above anal verge; Good Performance Status (Eastern Cooperative Oncology Group 0-1)
Exclusion Criteria
Concurrent Malignancy other than Rectal Cancer; No tolerance for Chemotherapy; Previous Pelvic Radiotherapy; Distant Metastasis; Impaired Renal Function.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Complications. Timepoint: At the Initiation of Radiotherapy up to one month after surgery. Method of measurement: Common terminology criteria for cancer related therapy adverse events.
- Secondary Outcome Measures
Name Time Method Tumor Downstaging. Timepoint: After Surgery. Method of measurement: Pathology Report.;Node Downstaging. Timepoint: After Surgery. Method of measurement: Pathology Report.;Pathologic Response. Timepoint: After Surgery. Method of measurement: Based on Pathology Report.